Featured
The AHA and ACC issued the first clinical guideline for cardiovascular-kidney-metabolic syndrome in June 2026. Here is what the four-stage system means for your care.
The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 recommendations with earlier screening, new PREVENT risk equations, universal Lp(a) testing, and lower LDL-C targets for many patients.
Congress and the FTC took aim at pharmacy benefit managers in 2026. Here is what changed, when it takes effect, and how it could lower your prescription costs.
The 2026 Dysautonomia International conference launched a new ME/CFS biobank, and recent studies identified potential blood-based biomarkers for post-exertional malaise. Here is what is ready now and what remains experimental.
:max_bytes(150000):strip_icc()/VWM-ADHDinWomenSignsandSymptoms_final-efbb964a72474f06a5f9b1eae2eec62c.png)
Perimenopause and ADHD share strikingly similar symptoms. A 2025 population study found women with ADHD report nearly double the rate of severe perimenopausal symptoms.
The EPA issued new interim guidance on PFAS destruction and disposal in April 2026, and NRDC warned that PFAS microplastics are a global contaminant found in human blood, placenta, lung tissue, and semen. Here is what to do now.
A June 2026 JACC subgroup analysis of the FLOW trial confirmed that semaglutide reduces major kidney events and death consistently across cardiovascular subgroups in type 2 diabetes and chronic kidney disease.
New studies show semaglutide can accelerate muscle loss in older adults with type 2 diabetes, especially at higher doses. Here is what clinicians recommend for protection.
Obstructive sleep apnea triggers hypoxia-driven kidney injury through inflammation and blood pressure spikes. New data confirm that consistent CPAP use slows kidney function decline in chronic kidney disease patients.
A European phase 2 trial found the existing epilepsy drug sulthiame reduced sleep apnea breathing interruptions by up to 47%. It is not a replacement for CPAP yet, but it is the strongest signal yet that a pill-based approach may work.
A June 2026 real-world study confirms fezolinetant improves hot flashes, depression, and anxiety. Here is what that means for women who cannot or choose not to use hormone therapy.
Enlarged prostate and prostate cancer share a name and a location, but they are not the same condition. Here is what 2025–2026 urology guidance says about BPH, screening, and when to worry.
Acid reflux affects roughly 20% of U.S. adults weekly. For many, PPIs are overprescribed and carry long-term risks. Here is the evidence-based path to relief without lifelong medication.
Prediabetes affects roughly 96 million U.S. adults, but GLP-1s are not the only answer. Here is what 2025-2026 evidence says about lifestyle, metformin, and when drugs fit.
TikTok pushes berberine as a natural GLP-1. Here is what 2025-2026 evidence says about the claim, the risks, and the reality.
A stubborn reading on medication panics patients. Here is what 2025-2026 evidence says about why pills lag and what actually lowers it.
The scale stops after early GLP-1 losses. Here is what 2025-2026 evidence says about plateaus, insulin, and what restarts progress.
Some women feel miserable starting hormone therapy. Here is what 2025-2026 evidence says about adjustment, red flags, and real relief.
